Replies to post #120295 on Biotech Values

[DewDiligence]

I wonder even how differentiated this Ablynx drug is from all of this competition in terms of efficacy/safety, if at all.

As noted in my reply to Peter, I think the main advantage relative to the existing TNF-a biologics may be in lower COGS.